In this podcast, Dr. Richard L. Schilsky describes ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study and what has been learned since it launched in 2016.
In this podcast, Dr. Allison Kurian and genetic counselor Kristen Mahoney Shannon discuss what people should know about their hereditary breast cancer risk, including how to know whether the condition may run in your family and what to expect if you will be receiving genetic counseling.
Read research from the July 2023 session of the ASCO Plenary Series, which highlights a study evaluating a potential maintenance therapy option for people with advanced or recurrent TP53 wild-type endometrial cancer.
The ASCO Annual Meeting is being held June 2 to 6. Research highlights from the day include using trastuzumab deruxtecan to treat HER2-expressing tumors and using CAR T-cell therapy to slow or stop multiple myeloma.
In this podcast, Dr. Petros Grivas and Dr. Marianne Dubard-Gault discuss what people with bladder cancer and their families should know about genetic testing.
In this “Cancer in My Community” post, Dr. Krittiya Korphaisarn shares what cancer is like in Thailand, including how cancer is treated and why the Thai government launched a genetic testing initiative in the country.
Read research from the August 2022 session of the ASCO Plenary Series, which features a study that evaluated how common it is for people with lung cancer to have inherited genetic mutations known to increase cancer risk.
In this podcast, experts discuss what people with early-stage lung cancer should know about molecular testing, including what it is, how it may be used in guiding treatment decisions, and several recent studies about its role in treatment planning.
At-home DNA tests have become increasingly popular in recent years. But are they actually helpful for detecting cancer risk? In this post, learn about at-home DNA tests for cancer risk and why it’s always best to get genetic screening done through your health care provider.
Lung cancer survivor Amanda Nerstad shares what it was like receiving a stage 4 diagnosis at age 39, the role genomic testing played in prolonging her quality of life, and how she and her family cope with the diagnosis.
